Philips Institute

Andrew Yeudall

Interim Director
Philips Institute of Oral and Craniofacial Molecular Biology
Member Scientist, The Philips Institute

 

Education

• 1979-1983: BSc (Hons) Biochemistry, University of Glasgow, Scotland
• 1979-1986: BDS Dentistry, University of Glasgow, Scotland
• 1987-1991: PhD Molecular Biology, University of Glasgow, Scotland

Professional Experience

• 2005-present Interim Director, The Philips Institute, Virginia Commonwealth University, Richmond, VA
• 2005-present Interim Chair, Department of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, VA
• 2003-present Associate Professor of Biochemistry, Virginia Commonwealth University, Richmond, VA
• 2002-present Associate Professor (with tenure), The Philips Institute, Virginia Commonwealth University, Richmond, VA
• 2002-present Member Scientist, Massey Cancer Center, Richmond, Virginia
• Clinical Senior Lecturer (with tenure), Depts. of Craniofacial Development and Oral & Maxillofacial Surgery, Guy’s  Hospital, King’s College London, UK.
• Associate Member, Cancer Biology and Therapy Interdisciplinary Research Group, GKT School of Medicine, King’s College London, UK

Honors

• 2005  Founding Fellow, International Academy of Oral Oncology
• 2004  Visiting Professor, Faculty of Dentistry, Thammasat, Chulalongkorn and Chiang Mai Universities, Thailand
• 2004  VCU School of Dentistry Research Award
• 2002  Steel Travel Award, Oral & Dental Research Trust
• 1996-present Editorial Board, Oral Oncology
• 1995  Reviewer, Advanced Technology Program, US Dept. of Commerce

Funded Research

• Signaling pathways in metastatic head and neck cancer cells. Commonwealth Health Research Board.
• Gene expression in metastatic head and neck cancer. Philip Morris USA, Inc.

Research Interests

Research in the lab centers around the molecular and cellular biology of head and neck squamous cell carcinoma (HNSCC), the sixth most prevalent malignancy in the US, and which is associated with considerable morbidity and mortality. We have previously reported deregulation of a number of growth regulatory pathways in HNSCC; these include elevated expression of the epidermal growth factor receptor (EGFR), which likely drives cell proliferation; and loss of cell cycle control by transforming growth factor beta (TGFβ) and the p53 and p16/ink4A tumor suppressors. Our current research investigates mechanisms whereby deregulation of EGF and TGFβ signaling can contribute to enhanced motility and invasion of HNSCC cells, with a view to designing novel strategies for blocking tumor cell metastasis, and identifying predictive markers for tumor spread. In addition, we are actively investigating the biological response of cells to chemotherapeutic agents, and the biochemical mechanisms that underpin the biology. These studies will help us to identify potential molecular targets whose activity might be modulated in order to improve the therapeutic response of HNSCC tumors.

Publications:

1. Edmiston JS, Yeudall WA, Chung TD, Lebman DA. Inability of TGFβ to cause SnoN degradation in esophageal cancer cells leads to resistance to TGFβ induced growth arrest. ancer Res 65, 4782-4788 (2005)
2. Yeudall WA, Miyazaki H, Ensley JF, Cardinali M, Gutkind JS, Patel V. Uncoupling of epidermal growth factor-dependent proliferation and invasion in a model of squamous carcinoma progression. Oral Oncol (2005, in press)
3. Wrighton KH, Prêle CM, Sunters A, Yeudall WA. Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity. Int j Cancer 112, 760-770 (2004)
4. Sunters A, Thomas DP, Yeudall WA, Grigoriadis AE. Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: Induction of cyclin A and enhanced CDK2 activity. J Biol Chem 279, 9882-9891(2004)
5. Yeudall WA, Wrighton KH. Cell cycle deregulation in head and neck cancer. In Head and Neck Cancer. Eds. Ensley JF, Lippman, S, Jacobs, J, Gutkind, JS. Academic Press. New York. pp101-116 (2003)
6. Yeudall WA. Henderson, B, Protein expression, analysis and proteomics. In Oxford Handbook of Dental Preclinical Sciences. Ed. Scully, C. Oxford University Press. Oxford. pp283-306 (2003)
7. Parkinson EK, Yeudall WA. The Epidermis. In Culture of Epithelial Cells. Eds. Freshney RI, Freshney MG. Wiley. pp65-94 (2002)
8. Patel V, Aldridge K, Ensley JF, Odell EW, Boyd A, Jones J, Gutkind JS, Yeudall WA. Overexpression of laminin-5 in squamous cell carcinomas of the head and neck. Int J Cancer 99, 583-588 (2002)
9.  Eveson JW, Yeudall WA. What is the evidence for the progression from benign to malignant pleomorphic adenoma? In Controversies in the Management of Salivary Gland Disease. Eds. McGurk M, Renehan A. Oxford University Press, Inc. New York, pp105-114 (2001)
10. Patel V, Ensley JF, Gutkind JS, Yeudall WA. p53-independent apoptosis induced by gamma-irradiation and bleomycin in head and neck squamous carcinoma cells. Int J Cancer 88, 737-743 (2000)
11. Castle JT, Cardinali M, Kratochvil FJ, Abbondanzo SL, Kessler HP, Auclair PL, Yeudall WA. p53 and cyclin D1 staining patterns of malignant and premalignant oral lesions in age-dependent populations. Oral Surg Oral Med Oral Pathol 88, 326-332 (1999)

Lab Members

   Current:

• Hiroshi Miyazaki, MD, Ph.D.                postdoctoral research associate
• Jacquelin LaClair, BS                           laboratory specialist
• Huixin Wang, BS                                   laboratory specialist
• Rachel J. Paccione                               graduate student
• Ryan K. Edmonds, BS                          summer student

    Previous:   

• David B. West, BS
• Katharine Wrighton, BSc, Ph.D.
• Cecilia M. Prêle, BSc, Ph.D.
• Manpreet Bhatti, BSc, Ph.D.
   

Links

International Academy of Oral Oncology
http://www.eastman.ucl.ac.uk/iaoo/index.html

Oral Oncology
http://www.sciencedirect.com/science/journal/13688375

Massey Cancer Center
http://www.vcu.edu/mcc

Philips Institute Home Page

Date last modified: 06/14/05